#repatha — Public Fediverse posts

Amgen CEO Bob Bradway announced that new clinical trial data show Repatha significantly reduces heart attack risk by 36% when combined with standard therapies, underscoring the importance of lowering LDL cholesterol for high-risk patients.
#YonhapInfomax #Amgen #Repatha #HeartAttackRisk #LDLCholesterol #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90246

Amgen CEO Bob Bradway announced that new clinical trial data show Repatha significantly reduces heart attack risk by 36% when combined with standard therapies, underscoring the importance of lowering LDL cholesterol for high-risk patients.
#YonhapInfomax #Amgen #Repatha #HeartAttackRisk #LDLCholesterol #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90246

Amgen CEO Bob Bradway announced that new clinical trial data show Repatha significantly reduces heart attack risk by 36% when combined with standard therapies, underscoring the importance of lowering LDL cholesterol for high-risk patients.
#YonhapInfomax #Amgen #Repatha #HeartAttackRisk #LDLCholesterol #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90246

Amgen CEO Bob Bradway announced that new clinical trial data show Repatha significantly reduces heart attack risk by 36% when combined with standard therapies, underscoring the importance of lowering LDL cholesterol for high-risk patients.
#YonhapInfomax #Amgen #Repatha #HeartAttackRisk #LDLCholesterol #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90246

Evolocumab Gains Expanded Indication for Primary Prevention

FDA has expanded the indication for evolocumab (#Repatha) to include patients at high risk for cardiovascular disease due to elevated LDL cholesterol levels

The PCSK9 inhibitor is now approved in high-risk adults without established disease to reduce the risk of major cardiovascular events (cardiovascular mortality, MI, stroke, unstable angina requiring hospitalization, or coronary revascularization)

Prior to the expanded indication, evolocumab only had approval for reducing the risk of CVD events (MI, stroke) in patients with established disease

https://www.tctmd.com/news/evolocumab-gains-expanded-indication-primary-prevention

Repatha is administered once every two weeks through a pen injector - I'm now on my third dose and side effects (insomnia, cold-like symptoms, back pain, dizziness, headaches, fatigue) are still there up to a week after each shot. I had hoped they would decrease but that hasn't happened, so I'll be informing my doctor I won't be taking a fourth shot.

Also will tell them that since every cholesterol meds I've ever taken makes me feel worse, I'll just stick to niacin.

#repatha #cholesterol